X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23) 23
ntrk (23) 23
humans (18) 18
oncology (18) 18
tumors (14) 14
etv6-ntrk3 gene fusion (13) 13
pathology (13) 13
larotrectinib (11) 11
ntrk fusion (10) 10
cancer (9) 9
entrectinib (8) 8
female (8) 8
gene fusion (7) 7
immunohistochemistry (7) 7
infantile fibrosarcoma (7) 7
male (7) 7
pan-trk (7) 7
acquired-resistance (6) 6
alk inhibitor (6) 6
animals (6) 6
expression (6) 6
trk (6) 6
tropomyosin (6) 6
adult (5) 5
cell biology (5) 5
fibrosarcoma (5) 5
gene fusions (5) 5
health aspects (5) 5
receptor, trka - genetics (5) 5
targeted therapy (5) 5
biomarkers, tumor - genetics (4) 4
carcinoma (4) 4
development and progression (4) 4
diagnosis (4) 4
etv6-ntrk3 (4) 4
genes (4) 4
genetic aspects (4) 4
hybridization (4) 4
infant (4) 4
kinases (4) 4
loxo-101 (4) 4
lung cancer (4) 4
lung neoplasms - drug therapy (4) 4
metastases (4) 4
middle aged (4) 4
mutation (4) 4
oncogene proteins, fusion - genetics (4) 4
open-label (4) 4
patient (4) 4
pediatrics (4) 4
precision medicine (4) 4
rearrangements (4) 4
receptor (4) 4
receptor, trkc - genetics (4) 4
ret (4) 4
review (4) 4
sarcoma (4) 4
secretory carcinoma (4) 4
subset (4) 4
surgery (4) 4
trk inhibitor (4) 4
aged (3) 3
alk (3) 3
article (3) 3
biomarkers, tumor - analysis (3) 3
braf (3) 3
breast-cancer (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
carcinoma, non-small-cell lung - genetics (3) 3
care and treatment (3) 3
chemotherapy (3) 3
congenital mesoblastic nephroma (3) 3
egfr (3) 3
etv (3) 3
fusions (3) 3
gene rearrangement (3) 3
growth-factor receptor (3) 3
hematology (3) 3
inhibitor entrectinib (3) 3
kinase (3) 3
landscape (3) 3
lung neoplasms - genetics (3) 3
lung-cancer (3) 3
magnetic resonance imaging (3) 3
medicine & public health (3) 3
metastasis (3) 3
mice (3) 3
molecular targeted therapy (3) 3
muscle proteins (3) 3
nervous system (3) 3
nsclc (3) 3
pharmacology & pharmacy (3) 3
phosphotransferases (3) 3
pyrimidines - therapeutic use (3) 3
receptor, trka - antagonists & inhibitors (3) 3
receptor, trka - metabolism (3) 3
ros1 (3) 3
signal transduction (3) 3
tyrosine kinase inhibitor (3) 3
young adult (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ONCOTARGETS AND THERAPY, ISSN 1178-6930, 2019, Volume 12, pp. 3171 - 3179
The development of deep-sequencing methods is now unveiling a new landscape of previously undetected gene fusion across different tumor types. Chromosomal... 
RET | TRANSFORMATION | larotrectinib | PAN-TRK | ETV6-NTRK3 | INHIBITOR ENTRECTINIB | KINASE | ACQUIRED-RESISTANCE | REARRANGEMENTS | resistance | ONCOGENE | chromosomal rearrangements | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | NTRK | CARCINOMA | Clinical trials | FDA approval | Tumors
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2019, Volume 30, Issue 2, pp. 325 - 331
Abstract Background NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective... 
Adult | Trk fusion cancer | Larotrectinib | Phase i | Ntrk gene fusion | larotrectinib | NTRK gene fusion | ONCOLOGY | ETV6-NTRK3 GENE FUSION | phase I | adult | TRK fusion cancer | NTRK FUSION | Original
Journal Article
Journal of Clinical Pathology, ISSN 0021-9746, 03/2019, Volume 72, Issue 3, pp. 187 - 190
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 03/2018, Volume 42, Issue 6, pp. 791 - 798
Tropomyosin receptor kinase (Trk) inhibitors have shown high response rates in patients with tumors harboring NTRK fusions. We identified 4 NTRK... 
uterine sarcoma | fibrosarcoma | NTRK | SURGERY | HYBRIDIZATION | PATHOLOGY | TUMORS | CANCER | GENE FUSIONS | DATABASE | TRK FAMILY | LOW-GRADE | RECEPTORS | ENDOMETRIAL STROMAL SARCOMA | EXPRESSION | Care and treatment | Sarcoma | Development and progression | Genetic aspects | Uterine tumors | Health aspects | Phosphotransferases | Gene fusion
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 08/2018, Volume 42, Issue 8, pp. 1052 - 1058
A number of oncogenic driver mutations have been identified in melanocytic nevi and melanoma, but translocations also play a role in tumorigenesis and provide... 
melanoma | pathology | immunohistochemistry | NTRK | SURGERY | ACQUIRED-RESISTANCE | OPEN-LABEL | TRAF2 | SINGLE-ARM | CANCER | BRAF-MUTANT | SPITZ NEVI | KIT | MUTATIONS | VEMURAFENIB | Enzymes | Care and treatment | Melanoma | Development and progression | Genetic aspects | Regulation | Health aspects | Phosphotransferases | Gene fusion
Journal Article
ESMO Open, ISSN 2059-7029, 03/2016, Volume 1, Issue 2, p. e000023
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are... 
NTRK | gene fusions | Molecular oncology | Target therapy
Journal Article
Lung Cancer Management, ISSN 1758-1966, 04/2016, Volume 5, Issue 1, pp. 1 - 4
Journal Article
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 01/2019, Volume 19, Issue 1, pp. 1 - 10
Introduction: TRK fusions occur across a wide range of cancers in children and adults. These fusions drive constitutive expression and ligand-independent... 
Larotrectinib | NTRK | TRK inhibitor | TRK fusion | neurotrophin receptor | INFANTILE FIBROSARCOMA | CONGENITAL MESOBLASTIC NEPHROMA | PROTEIN-TYROSINE KINASE | TROPOMYOSIN | CANCER | RECEPTOR KINASE | ONCOLOGY | ETV6-NTRK3 GENE FUSION | THYROID-CARCINOMA | PATIENT | NTRK FUSION
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 04/2019, Volume 43, Issue 4, pp. 435 - 445
Pediatric mesenchymal tumors harboring variant NTRK fusions (ETV6-negative) are being increasingly described; however, the histologic and clinical features of... 
NTRK | soft tissue sarcoma | TRK | infantile fibrosarcoma | pediatric | ALK | SURGERY | LAROTRECTINIB | PAN-TRK | MANAGEMENT | TISSUE | CONGENITAL MESOBLASTIC NEPHROMA | PATHOLOGY | SUBSET | CHILDREN | ETV6-NTRK3 GENE FUSION | Tumors in children | Development and progression | Genetic aspects | Sarcoma | Health aspects | Gene fusion
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 10/2018, Volume 65, Issue 10, pp. e27271 - n/a
Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6–NTRK fusion, which... 
ETV6–NTRK | mesoplastic nephroma | larotrectinib | bone metastasis | TRK inhibitor | ONCOLOGY | INFANTILE FIBROSARCOMA | RECURRENT | ETV6-NTRK3 GENE FUSION | PEDIATRICS | ETV6-NTRK | HEMATOLOGY | INFANCY | Genetic disorders | Metastasis | Neonates | Signal transduction | Bone remodelling | Tropomyosin | Infants | Bone | Metastases
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 07/2018, Volume 42, Issue 7, pp. 927 - 935
Activating neurotrophic receptor kinase (NTRK) fusions define certain pediatric mesenchymal tumors, including infantile fibrosarcoma and cellular mesoblastic... 
immunohistochemistry | NTRK | soft tissue sarcoma | Trk | pediatric | SURGERY | INFANTILE FIBROSARCOMA | ETV6-NTRK3 GENE FUSION | PATHOLOGY | SUBSET | Enzymes | Care and treatment | Development and progression | Genetic aspects | Regulation | Phosphotransferases | Health aspects | Cancer in children
Journal Article
Pathology - Research and Practice, ISSN 0344-0338, 09/2019, p. 152662
Journal Article
The Oncologist, ISSN 1083-7159, 03/2017, Volume 22, Issue 3, pp. 255 - 263
Journal Article